The antiplatelet activity of DC-015, a newly synthesized quinazoline derivative was determined in human platelet-rich plasma. From the binding studies, the Ki values of DC-015 for α1-, α2- adrenoceptors and 5-HT1, 5-HT2 receptors were about 0.21(nM), 0.59(μM), 0.16(μM) and 0.38(μM), respectivity. On the otherhand, the Ki values of prazosin for α1- and α2-adrenoceptors were about 0.19(nM) and 4.8(μM), respectivity. Experimental results indicated that DC-015 dose-dependently inhibited noradrenaline (10μM)-induced platelet aggregation in human platelet-rich plasma. At 20μM, DC-015 would completely inhibit platelet aggregation induced by noradrenaline. A high concentration of prazosin (>30mM) caused sligh inhibition of aggregation. Furthermore, DC-015 (2μM) significantly increased the cyclic AMP level in human platelet-rich plasma, whereas, prazosin significantly increased cyclic AMP level only at higher concentrations (100μM). We can conclude that DC-015 inhibited noradrenaline-induced platelet aggregation mainly through binding to cc2-receptor on platelets, resulting in inhibiting platelet aggregation.